RPM - Supplements

Kevzara (Sarilumab): A Novel IL-6 Receptor Antagonist for Rheumatoid Arthritis
Sarilumab (Kevzara) is a novel interleukin (IL)-6 receptor inhibitor that was approved by the US Food and Drug Administration (FDA) on May 22, 2017, for the treatment of adults with moderately or severely active RA who have had an inadequate response or intolerance to 1 or more DMARDs. Read More ›

Beyond TNF-α: Alternate Mechanisms of Action in Rheumatoid Arthritis

An increased understanding of the molecular pathogenesis of RA has led to significant advances in biologic therapies in the past 15 years and has dramatically changed the treatment paradigm for RA.3 Currently, 4 classes of biologic DMARDs are available, including (1) the tumor necrosis factor (TNF)-α inhibitors adalimu­mab, certolizumab pegol, etanercept, golimumab, and infliximab; (2) abatacept, which blocks T-cell costimulation via anti-CD80/86 inhibition; (3) the anti-CD20 agent that causes B-cell depletion, rituximab; and (4) the interleukin (IL)-6 receptor (IL-6R) blocker, tociliz­umab.

Read More ›

Subscribe to
Rheumatology Practice Management

Stay up to date with rheumatology news & updates by subscribing to recieve the free RPM print publications or weekly e‑Newsletter.

I'd like to recieve: